title: Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
abstract: Vaccine efficacies against typical pertussis after household exposure to Bordetella pertussis were estimated to be 75.4% for an acellular five-component vaccine, 42.4% for an acellular two-component vaccine, and 28.5%, for a licensed US whole cell vaccine, compared to placebo. Logistic regression analyses demonstrated statistically significant correlations between clinical protection and the presence of IgG antibodies against pertactin, fimbriae 2/3 and pertussis toxin in pre-exposure sera. Multicomponent pertussis vaccines of proven high efficacy in recent Swedish NIAID-sponsored efficacy trials induced higher antibody levels against pertactin and fimbriae 2/3 than less efficacious vaccines. Anti-pertactin, anti-fimbriae 2/3, and anti-PT may be used as surrogate markers of protection for multicomponent acellular and whole-cell vaccines against pertussis.
authors.affiliation: Sachs' Children's Hospital, Stockholm, Sweden.
authors.forename: J
authors.initials: J
authors.lastname: Storsaeter
authors.forename: H O
authors.initials: HO
authors.lastname: Hallander
authors.forename: L
authors.initials: L
authors.lastname: Gustafsson
authors.forename: P
authors.initials: P
authors.lastname: Olin
mesh_terms: D018829:Adhesins, Bacterial / Q000276:immunology; D000907:Antibodies, Bacterial / Q000097:blood*; D000942:Antigens, Bacterial / Q000276:immunology; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D001426:Bacterial Proteins / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D001886:Bordetella pertussis / Q000276:immunology*; D017714:Community-Acquired Infections; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000276:immunology*; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D036781:Fimbriae Proteins; D010861:Fimbriae, Bacterial / Q000276:immunology; D006388:Hemagglutinins / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007223:Infant; D008297:Male; D017817:Nasal Lavage Fluid / Q000382:microbiology; D009305:Nasopharynx / Q000382:microbiology; D037342:Pertussis Toxin; D010567:Pertussis Vaccine / Q000276:immunology*; D016896:Treatment Outcome; D010566:Virulence Factors, Bordetella / Q000276:immunology; D014917:Whooping Cough / Q000276:immunology / Q000517:prevention & control / Q000635:transmission
chemical_list: D018829:Adhesins, Bacterial; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D015415:Biomarkers; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D006388:Hemagglutinins; D007074:Immunoglobulin G; D010567:Pertussis Vaccine; D010566:Virulence Factors, Bordetella; C065273:filamentous hemagglutinin adhesin, Bordetella pertussis; C101541:fim2 protein, Bordetella; D036781:Fimbriae Proteins; C068929:pertactin; D037342:Pertussis Toxin